Ovarian Function Assessment

Primary Hormone Panel

• FSH is the hallmark marker for ovarian function assessment and should be measured during cycle days 2-5 of the menstrual cycle, as recommended by the American Society of Clinical Oncology 1, 2
• For women with amenorrhea, FSH should be measured randomly rather than waiting for a specific cycle day, according to the American Society of Clinical Oncology 1

Additional Ovarian Reserve Markers

• AMH represents the best endocrine marker for assessing age-related decline in ovarian reserve in healthy women, as stated by the American Society of Clinical Oncology 1, 2
• No recommendations exist for using AMH in diagnosing premature ovarian insufficiency, as its diagnostic value remains unestablished, according to the American Society of Clinical Oncology 1, 2

Special Clinical Contexts

• Laboratory evaluation is not recommended as primary surveillance in asymptomatic at-risk women; testing should be triggered by menstrual changes or POI symptoms, as recommended by the American Society of Clinical Oncology 1, 2

Critical Testing Limitations

• FSH is unreliable in women taking tamoxifen, toremifene, or LHRH agonists/antagonists, as stated by the National Comprehensive Cancer Network 3
• Menopausal status cannot be determined while receiving ovarian function suppression, according to the National Comprehensive Cancer Network 3
• Aromatase inhibitors can stimulate ovarian function; vaginal bleeding while on AI requires immediate physician contact, as recommended by the National Comprehensive Cancer Network 3

Timing and Monitoring Protocols

• Women under age 60 who are amenorrheic for ≤12 months prior to adjuvant endocrine therapy should be monitored, as recommended by the National Comprehensive Cancer Network 3
• Prior to next dose of GnRH agonist, particularly in women under age 45, monitoring is recommended, according to the National Comprehensive Cancer Network 3

Common Pitfalls to Avoid

• Do not test FSH in women currently on tamoxifen or ovarian suppression therapy, as results will be unreliable, as stated by the National Comprehensive Cancer Network 3

Ovarian Function Tests

Primary Diagnostic Tests

• The American College of Radiology recommends transvaginal ultrasound as the primary imaging modality for ovarian assessment, with antral follicle count (AFC) being a strong positive correlation with anti-Müllerian hormone (AMH) levels 4, 5, 6
• The American College of Radiology suggests that an AFC of <5 and ovarian volume <3 cm³ indicates diminished ovarian reserve 4, 6
• Elevated follicle-stimulating hormone (FSH) levels indicate diminished ovarian reserve, and should be measured during the early follicular phase (days 2-3 of menstrual cycle) 7, 8
• Estradiol levels should be measured alongside FSH during the early follicular phase to help interpret FSH results, as normal FSH with elevated estradiol may mask diminished ovarian reserve 7, 8

Clinical Applications and Interpretation

• For patients with suspected premature ovarian insufficiency (POI), the American College of Obstetricians and Gynecologists recommends evaluating menstrual history, FSH and estradiol levels, AMH levels, and AFC via transvaginal ultrasound 7, 8, 9
• The American College of Radiology recommends that diagnostic criteria for polycystic ovarian morphology (PCOM) include ≥25 follicles (2-9 mm in diameter) in at least one ovary and ovarian volume >10 mL 4, 6

Special Considerations

• The American Society of Clinical Oncology recommends that female cancer survivors treated with gonadotoxic therapies undergo regular ovarian function assessment, with higher risk in patients treated with alkylating agents, cyclophosphamide and procarbazine, or radiotherapy potentially exposing the ovaries 9, 10
• The National Comprehensive Cancer Network recommends that FSH is not a reliable marker of menopausal status in women with prior chemotherapy, pelvic radiation exposure, or those on tamoxifen 11

Laboratory Tests to Diagnose Ovarian Failure

Essential Diagnostic Laboratory Tests

• The American Academy of Family Physicians recommends measuring Prolactin level to exclude hyperprolactinemia as a cause of amenorrhea in women with menstrual irregularities 12, 13
• The American Academy of Family Physicians suggests checking Thyroid-stimulating hormone (TSH) to rule out thyroid disease, which can cause ovulatory dysfunction and is associated with autoimmune ovarian failure 12, 13

Diagnosis and Laboratory Testing for Menopause

Indications for Laboratory Testing

• The American College of Obstetricians and Gynecologists recommends laboratory evaluation for women under age 45 with suspected premature ovarian insufficiency or early menopause, women with unclear menopausal status, and women with amenorrhea of uncertain cause 14, 15
• The National Comprehensive Cancer Network suggests that women on medications such as tamoxifen or chemotherapy require laboratory confirmation of menopausal status 14

Diagnostic Criteria for Menopause

• The American College of Obstetricians and Gynecologists states that for women under age 60, menopause can be confirmed by amenorrhea for 12 or more months and FSH and estradiol in the postmenopausal range 14
• The National Comprehensive Cancer Network recommends that prior bilateral oophorectomy is sufficient for diagnosing surgical menopause 16, 14

Laboratory Tests

• The American College of Obstetricians and Gynecologists recommends measuring FSH and estradiol during the early follicular phase to help interpret FSH results 14, 17
• The National Comprehensive Cancer Network suggests that LH:FSH ratio <1 may indicate functional hypothalamic amenorrhea rather than menopause 15

Special Populations

• The National Comprehensive Cancer Network recommends serial FSH and estradiol measurements for women with prior chemotherapy or pelvic radiation 14
• The American College of Obstetricians and Gynecologists states that women with therapy-induced amenorrhea may still have intact ovarian function and should be counseled about pregnancy risk despite amenorrhea 16

AMH Measurement and Ovarian Reserve Assessment

Importance of Age-Specific Reference Ranges

• Age-specific reference ranges are vital for AMH levels, as they are high in adolescence and fall with age, particularly after menopause, according to the American Society of Clinical Oncology 18

Technical Considerations for AMH Assays

• Significant technical issues exist regarding AMH assays, including lack of international standardization and variability in sample handling, which can affect result interpretation more than menstrual cycle timing, as reported in Trends in Endocrinology and Metabolism 18, 19

Guidelines for Interpreting Anti‑Müllerian Hormone (AMH) Levels

Reference‑Range Interpretation

• Age‑specific reference ranges are essential because AMH concentrations change markedly across the reproductive lifespan and cannot be evaluated with a single universal cutoff. 20

Low AMH and Ovarian Reserve

• In women in their early 30s, AMH values below 1.0 ng/mL are generally classified as low and may suggest diminished ovarian reserve, although this does not reliably predict fertility outcomes in the broader population. 21

Assay Standardization and Platform Variability

• Significant technical limitations affect AMH testing, including the absence of an international assay standard and variability introduced by sample handling, which can alter result interpretation. 22
• Different assay platforms (e.g., Gen II ELISA, Elecsys) can produce disparate absolute AMH values; therefore, clinicians must apply assay‑specific reference ranges when interpreting results. [22][21]

Clinical Decision Thresholds

• Cutoffs derived from the 95th percentile should not be used for clinical decision‑making because they do not represent biologically meaningful thresholds. [20][22]

Contextual Interpretation

• AMH results should be evaluated alongside menstrual regularity, reproductive intentions, and other ovarian function markers rather than in isolation. 20

Interpretation of Markedly Elevated AMH Levels in Women

Diagnostic Significance

• An anti‑Müllerian hormone (AMH) concentration of 146 pmol/L (≈20.4 ng/mL) is markedly elevated and strongly suggests polycystic ovary syndrome (PCOS), especially when accompanied by oligomenorrhea or clinical hyperandrogenism. 23
• An AMH value of 146 pmol/L exceeds the typical diagnostic threshold for polycystic ovarian morphology (PCOM), which is generally 20–50 pmol/L and varies with age and assay platform. 23

Assay‑Specific Interpretation

• Different AMH assay platforms (e.g., Gen II ELISA, Elecsys) yield disparate absolute values; clinicians must apply assay‑specific reference ranges rather than a universal cut‑off. 23
• The reported result should be interpreted using the reference range supplied by the laboratory that performed the specific assay. 23
• Population‑based 95th‑percentile cutoffs lack biological relevance and should not be used for individual clinical decision‑making. 23

Diagnostic Accuracy

• The ability of AMH to identify PCOM shows area‑under‑the‑curve (AUC) values ranging from 0.67 to 0.92, reflecting moderate to high diagnostic performance but with considerable overlap between PCOS and non‑PCOS populations. 23

Clinical Evaluation Recommendations

• When an elevated AMH is identified, clinicians should assess menstrual patterns for oligomenorrhea or amenorrhea and evaluate signs of clinical hyperandrogenism such as hirsutism and acne. 23

Reproductive Outcomes

• Current evidence indicates that high AMH levels do not increase the risk of miscarriage; meta‑analyses show no difference in miscarriage rates between women with medium versus high AMH concentrations. [24][25]